Alectorincis A Clinical Stage Biotechnology Company Based In South San Franciscocaliforniafounded In 2013The Company Focuses On Developing Immuno Neurology Therapies For Neurodegenerative Diseasesincluding Alzheimer S Disease And Frontotemporal Dementiaftd Alector Aims To Improve Patientsquality Of Life By Integrating Immunologyneurologyand Genetics In Its Treatment Approaches Alector S Pipeline Features Investigational Monoclonal Antibodies Designed To Address Immune Dysfunction In Neurodegenerationkey Candidates Include Al001Latozinemab Which Is In Phase 3 Trials For Ftd Patients With Progranulin Gene Mutationsand Al101Developed In Partnership With Gskthe Company Collaborates With Pharmaceutical Partners Like Abbvie And Gsk To Advance Its Research And Development Effortsalector Went Public In 2019Raising Significant Funds To Support Its Ongoing Projects
